- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-small cell lung cancer (NSCLC)
- Meeting Date: July 2024
- Public Summary Document (PSD) July 2024 PBAC Meeting - (PDF 1.1MB)
- Public Summary Document (PSD) July 2024 PBAC Meeting - (Word 1MB)
Selpercatinib – July 2024
Selpercatinib; Capsule 40 mg, Capsule 80 mg; Retevmo®
Last updated
30 May 2025